Other factors such as insurance coverage, cost, availability, and patient preference for administration likely impacted which GLP-1RAs were used
5-Amino-1MQ/NAD/MOTS-C Atomizer Rated 0 out of 5 $ 85.00 9-ME-BC 15mg/60qty Dry Fill Rated 0 out of 5 $ 69.99 9-ME-BC 5mg/mL (15mL) Transdermal Rated 0 out of 5 $ 64.99 Adalank Spray Rated 0 out of 5 $ 74.99 Adamax Spray Rated 0 out of 5 $ 75.00 Aminotadalafil 10mg/60qty Dry Fill Rated 0 out of 5 $ 65.00 ATX-304 100mg per unit/ 60 qty Rated 0 out of 5 $ 125.00 BAC Water (3mL, 10mL, 30mL) Rated 0 out of 5 $ 6.00 $ 30.00Price range: $ 6.00 through $ 30.00 Add to Cart This product has multiple variants
Across heterogeneous study designs and populations, GLP-receptor agonist use was generally associated with a lower incidence of glaucoma
Chandel NS, Trzyna WC, McClintock DS, Schumacker PT
Of the 710 patients with type 2 diabetes, 194 were on GLP-1 medication, and 516 were on non-GLP-1 RA medication
A clinical study of HMGB1 and K18 measured by ELISA and immunoblot (Antoine et al